Juno shares up 29% as FDA allows resumption of clinical trial for cancer drug
Juno Therapeutics Inc. shares rose nearly 30% late Tuesday after the pharmaceutical company said the Food and Drug Administration allowed it to resume the mid-stage clinical trial of a cancer drug put on hold last week after two deaths. The drug, known as JCAR15, is supplied to patients suffering from an acute form of leukemia. Shares of Juno had ended the regular session up 1.7%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.